In essentially 100% of MRTs SNF5 is subject to biallelic inactivation; while in synovial sarcoma assembly of SS18-SSX into BAF complexes leads to eviction and proteasomal degradation of SNF5. The gene discussed is SSX2; the disease is synovial sarcoma.